Physician profile
Nicholas V Papapietro
NPI 1720028061
$1,519.70
in general payments reported to CMS, 2019-2025
12 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $801 · 2020: $128 · 2021: $43.85 · 2022: $231 · 2023: $34.27 · 2024: $132 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $315.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $479.95 | 2019-2025 | |
| Abbott Laboratories | $234.72 | 2019-2020 | |
| Terumo Medical Corporation | $173.22 | 2022 | |
| Pfizer INC. | $146.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.83 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $107.64 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $73.96 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.27 | 2024 | Camzyos |
| Merck Sharp & Dohme LLC | $39.37 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $38.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.38 | 2019-2020 | |
| Novo Nordisk INC | $25.32 | 2025 | Rivfloza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Papapietro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.